- ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma2021 | Lékařská fakulta v Hradci Králové, Ústřední knihovna
- Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial2007 | Lékařská fakulta v Plzni
- Fáze III studie kombinace erlotinib s cisplatinou a gencitabenem u pokročilého nemalobuněčného karcinomu plic: Tarcena - Studie výzkumu karcinomu plic2007 | 1. lékařská fakulta, Lékařská fakulta v Plzni
- Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study2017 | 2. lékařská fakulta
- Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study2021 | 2. lékařská fakulta
- The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma2022 | Lékařská fakulta v Hradci Králové
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma2019 | 1. lékařská fakulta
- A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)2017 | Lékařská fakulta v Hradci Králové
- Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma2019 | 1. lékařská fakulta
- Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)2021 | 1. lékařská fakulta
- Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations : Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies2015 | 1. lékařská fakulta
- Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study2022 | 1. lékařská fakulta
- Long-term efficacy and safety adalimumab in children with juvenile rheumatoid arthritis (JRA): converting from body-surface-area dosing to weight-based fixed dosing in the open-label extension (OLE) of a phase III studyPublikace bez příslušnosti k fakultě
- Účinnost azacitidinu ve srovnání s konvenční léčbou u vysoce rizikových myelodysplastických syndromů: randomizovaná, otevřená studie fáze III2009 | Publikace bez příslušnosti k fakultě
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study2009 | Publikace bez příslušnosti k fakultě
- Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study2018 | Publikace bez příslušnosti k fakultě
- Pharmacokinetics, efficacy and safety of IMMUNATE (R) Solvent/Detergent (IMMUNATE (R) S/D) in previously treated patients with severe hemophilia A: Results of a prospective, multicenter, open-label phase III study2008 | 2. lékařská fakulta
- Setrvalá dlouhodobá účinnost a bezpečnost adalimumabu u dětských pacientů se závažnou chronickou ložiskovou psoriázou z randomizované, dvojitě zaslepené studie fáze III2020 | Lékařská fakulta v Plzni
- A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA2020 | 1. lékařská fakulta
- Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression2007 | 1. lékařská fakulta
- Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer2008 | 3. lékařská fakulta
- A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease2010 | 3. lékařská fakulta
- Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study2019 | Publikace bez příslušnosti k fakultě
- A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy2017 | 1. lékařská fakulta
- Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents2016 | 1. lékařská fakulta
- Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression(aEuro)2016 | Publikace bez příslušnosti k fakultě
- Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-0897113; Silva Study)2005 | 3. lékařská fakulta
- Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients2017 | Publikace bez příslušnosti k fakultě
- Efficacy and safety of exenatide as add-on therapy for patients with type 2 diabetes with an intensive insulin regimen : A randomized double-blind trial2021 | Lékařská fakulta v Plzni
- Komentář ke studii - Randomizovaná studie fáze III FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab v léčbě pravní linie mCRC s wild-type KRAS: německá studie AIO KRK-0306 (FIRE-3)2013 | 1. lékařská fakulta